BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tepasse PR, Hafezi W, Lutz M, Kühn J, Wilms C, Wiewrodt R, Sackarnd J, Keller M, Schmidt HH, Vollenberg R. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol 2020;190:185-8. [PMID: 32557623 DOI: 10.1111/bjh.16896] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 27.5] [Reference Citation Analysis]
Number Citing Articles
1 Martínez-Urbistondo M, Gutiérrez-Rojas Á, Andrés A, Gutiérrez I, Escudero G, García S, Gutiérrez A, Sánchez E, Herráiz J, De La Fuente S, Callejas A, De Mendoza C, Moreno-Torres V. Severe Lymphopenia as a Predictor of COVID-19 Mortality in Immunosuppressed Patients. J Clin Med 2021;10:3595. [PMID: 34441891 DOI: 10.3390/jcm10163595] [Reference Citation Analysis]
2 Vollenberg R, Tepasse P, Lorentzen E, Nowacki TM. Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study. JPM 2022;12:694. [DOI: 10.3390/jpm12050694] [Reference Citation Analysis]
3 Kronbichler A, Anders HJ, Fernandez-Juárez GM, Floege J, Goumenos D, Segelmark M, Tesar V, Turkmen K, van Kooten C, Bruchfeld A; Immunonephrology Working Group of the ERA-EDTA (European Renal Association – European Dialysis, Transplant Association). Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. Nephrol Dial Transplant 2021:gfab064. [PMID: 33693778 DOI: 10.1093/ndt/gfab064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
4 Lang N, Kuruvilla J. Evolving management strategies for lymphomas during the COVID-19 pandemic. Leuk Lymphoma. 2020;1-19. [PMID: 33356697 DOI: 10.1080/10428194.2020.1861277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Fagni F, Simon D, Tascilar K, Schoenau V, Sticherling M, Neurath MF, Schett G. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol 2021;3:e724-36. [PMID: 34485930 DOI: 10.1016/S2665-9913(21)00247-2] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Järhult JD, Hultström M, Bergqvist A, Frithiof R, Lipcsey M. The impact of viremia on organ failure, biomarkers and mortality in a Swedish cohort of critically ill COVID-19 patients. Sci Rep 2021;11:7163. [PMID: 33785784 DOI: 10.1038/s41598-021-86500-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Quartuccio L, Treppo E, Binutti M, Del Frate G, De Vita S. Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis. Rheumatology (Oxford) 2021;60:3476-7. [PMID: 33609106 DOI: 10.1093/rheumatology/keab175] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
8 Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Rituximab for the treatment of multiple sclerosis: a review. J Neurol 2021. [PMID: 33416999 DOI: 10.1007/s00415-020-10362-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
9 Sendi P, Razonable RR, Nelson SB, Soriano A, Gandhi RT. First-generation Oral Antivirals Against SARS-CoV-2. Clinical Microbiology and Infection 2022. [DOI: 10.1016/j.cmi.2022.04.015] [Reference Citation Analysis]
10 Schulze-Koops H, Krueger K, Vallbracht IV, Hasseli R, Skapenko A. Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al' by Benucci et al. Ann Rheum Dis 2020:annrheumdis-2020-218686. [PMID: 32753421 DOI: 10.1136/annrheumdis-2020-218686] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Laubscher F, Cordey S, Friedlaender A, Schweblin C, Noetzlin S, Simand PF, Bordry N, De Sousa F, Pigny F, Baggio S, Getaz L, Dietrich PY, Kaiser L, Vu DL. SARS-CoV-2 Evolution among Oncological Population: In-Depth Virological Analysis of a Clinical Cohort. Microorganisms 2021;9:2145. [PMID: 34683466 DOI: 10.3390/microorganisms9102145] [Reference Citation Analysis]
12 Hatami P, Balighi K, Nicknam Asl H, Aryanian Z. COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus. Dermatol Ther 2021;:e15216. [PMID: 34811862 DOI: 10.1111/dth.15216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Martinot M, Jary A, Fafi-Kremer S, Leducq V, Delagreverie H, Garnier M, Pacanowski J, Mékinian A, Pirenne F, Tiberghien P, Calvez V, Humbrecht C, Marcelin AG, Lacombe K. Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19. Clin Infect Dis 2020:ciaa1474. [PMID: 32986807 DOI: 10.1093/cid/ciaa1474] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 13.5] [Reference Citation Analysis]
14 Ferrari S, Caprioli C, Weber A, Rambaldi A, Lussana F. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. Leuk Lymphoma. 2021;1-9. [PMID: 33461387 DOI: 10.1080/10428194.2021.1872070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
15 Li G, Ruan S, Zhao X, Liu Q, Dou Y, Mao F. Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses. Comput Struct Biotechnol J 2021;19:1-15. [PMID: 33312453 DOI: 10.1016/j.csbj.2020.11.056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
16 Moutinho-Pereira S, Calisto R, Sabio F, Guerreiro L. High-titre convalescent plasma therapy for an immunocompromised patient with systemic lupus erythematosus with protracted SARS-CoV-2 infection. BMJ Case Rep 2021;14:e244853. [PMID: 34433539 DOI: 10.1136/bcr-2021-244853] [Reference Citation Analysis]
17 Vollenberg R, Tepasse P, Kühn JE, Hennies M, Strauss M, Rennebaum F, Schomacher T, Boeckel G, Lorentzen E, Bokemeyer A, Nowacki TM. Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2. Biomedicines 2022;10:171. [DOI: 10.3390/biomedicines10010171] [Reference Citation Analysis]
18 Bonelli M, Aletaha D. Response to: Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al. Ann Rheum Dis 2021;80:e167. [PMID: 34340982 DOI: 10.1136/annrheumdis-2021-220997] [Reference Citation Analysis]
19 Vallet N, Chevret S, Feghoul L, Aguinaga L, Bondeelle L, Kaphan E, Bertinchamp R, Soret J, Villesuzanne C, De Castro N, Sebert M, Boutboul D, Lengline E, Tudesq JJ, Rabian F, Adès L, Xhaard A, Di Blasi R, Raffoux E, Galicier L, Le Goff J, Delaugerre C, Bergeron A, Harel S; Saint-Louis CORE group. Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital. Blood Cancer J 2021;11:129. [PMID: 34262018 DOI: 10.1038/s41408-021-00512-5] [Reference Citation Analysis]
20 Porzionato A, Emmi A, Stocco E, Barbon S, Boscolo-Berto R, Macchi V, De Caro R. The potential role of the carotid body in COVID-19. Am J Physiol Lung Cell Mol Physiol 2020;319:L620-6. [PMID: 32755325 DOI: 10.1152/ajplung.00309.2020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
21 Hueso T, Pouderoux C, Péré H, Beaumont AL, Raillon LA, Ader F, Chatenoud L, Eshagh D, Szwebel TA, Martinot M, Camou F, Crickx E, Michel M, Mahevas M, Boutboul D, Azoulay E, Joseph A, Hermine O, Rouzaud C, Faguer S, Petua P, Pommeret F, Clerc S, Planquette B, Merabet F, London J, Zeller V, Ghez D, Veyer D, Ouedrani A, Gallian P, Pacanowski J, Mékinian A, Garnier M, Pirenne F, Tiberghien P, Lacombe K. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood 2020;136:2290-5. [PMID: 32959052 DOI: 10.1182/blood.2020008423] [Cited by in Crossref: 86] [Cited by in F6Publishing: 88] [Article Influence: 43.0] [Reference Citation Analysis]
22 Andreica I, Kiefer D, Rezniczek GA, Jast R, Buehring B, Kiltz U, Baraliakos X, Braun J. Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al. Ann Rheum Dis. [DOI: 10.1136/annrheumdis-2020-218609] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
23 Grammatikos A, Donati M, Johnston SL, Gompels MM. Peripheral B Cell Deficiency and Predisposition to Viral Infections: The Paradigm of Immune Deficiencies. Front Immunol 2021;12:731643. [PMID: 34527001 DOI: 10.3389/fimmu.2021.731643] [Reference Citation Analysis]
24 Woźniak K, Sachs W, Boguradzki P, Basak GW, Stec R. Chemotherapy During Active SARS-CoV2 Infection: A Case Report and Review of the Literature. Front Oncol 2021;11:662211. [PMID: 33912468 DOI: 10.3389/fonc.2021.662211] [Reference Citation Analysis]
25 Varley CD, Winthrop KL. Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections). Curr Rheumatol Rep 2021;23:74. [PMID: 34269903 DOI: 10.1007/s11926-021-01037-3] [Reference Citation Analysis]
26 Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D, Hofer P, Perkmann T, Haslacher H, Thalhammer R, Winkler S, Blüml S, Stiasny K, Aberle JH, Smolen JS, Heinz LX, Aletaha D, Bonelli M. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis 2021:annrheumdis-2021-220781. [PMID: 34285048 DOI: 10.1136/annrheumdis-2021-220781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
27 Nilius-Eliliwi V, Mika T, Baraniskin A, Wünnenberg M, Maslova M, Boy C, Klein-Scory S, Schroers R, Vangala D. Successful Chimeric Antigen Receptor (CAR) T-Cell Treatment in Aggressive Lymphoma Despite Coronavirus Disease 2019 (CoVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication - Case Report. Front Oncol 2021;11:706431. [PMID: 34336692 DOI: 10.3389/fonc.2021.706431] [Reference Citation Analysis]
28 Bonek K, Roszkowski L, Massalska M, Maslinski W, Ciechomska M. Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. Cells 2021;10:323. [PMID: 33557301 DOI: 10.3390/cells10020323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Lee EJ, Liu X, Hou M, Bussel JB. Immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol 2021;193:1093-5. [PMID: 33855698 DOI: 10.1111/bjh.17457] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Capoluongo E, Nardelli C, Esposito MV, Buonomo AR, Gelzo M, Pinchera B, Zappulo E, Viceconte G, Portella G, Setaro M, Gentile I, Castaldo G. Case Report: Discovery a Novel SARS-CoV-2 Variant in a Six-Months Long-Term Swab Positive Female Suffering From Non-Hodgkin Lymphoma. Front Oncol 2021;11:705948. [PMID: 34354952 DOI: 10.3389/fonc.2021.705948] [Reference Citation Analysis]
31 Burgener S, Rochat P, Dollenmaier G, Benz G, Kistler AD, Fulchini R, Koirala J. Progression of COVID-19 in a Patient on Anti-CD20 Antibody Treatment: Case Report and Literature Review. Case Reports in Infectious Diseases 2022;2022:1-5. [DOI: 10.1155/2022/8712424] [Reference Citation Analysis]
32 Mansi L, Spehner L, Daguindau E, Bouiller K, Almotlak H, Stein U, Bouard A, Kim S, Klajer E, Jary M, Meynard G, Vienot A, Nardin C, Bazan F, Lepiller Q, Westeel V, Adotévi O, Borg C, Kroemer M. Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients. Eur J Cancer 2021;150:1-9. [PMID: 33882374 DOI: 10.1016/j.ejca.2021.03.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
33 Martín Navarro JA, Cintra Cabrera M, Proccacini F, Muñoz Rodríguez J, Roldán Cortés D, Lucena Valverde R, Ortega Díaz M, Puerta Carretero M, Gil Herrera J, Jaldo Rodríguez MT, Albalate Ramón M, Corchete Prats E, Medina Zahonero L, de Sequera Ortiz P, Alcázar Arroyo R. More difficult still: Treating severe rapidly progressive glomerulonephritis in the context of COVID-19 pneumonia. Nefrología (English Edition) 2022. [DOI: 10.1016/j.nefroe.2020.12.007] [Reference Citation Analysis]
34 Hagman K, Hedenstierna M, Rudling J, Gille-Johnson P, Hammas B, Grabbe M, Jakobsson J, Dillner J, Ursing J. Duration of SARS-CoV-2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID-19: a cohort study. Diagn Microbiol Infect Dis 2021;102:115595. [PMID: 34896666 DOI: 10.1016/j.diagmicrobio.2021.115595] [Reference Citation Analysis]
35 Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, Pertuiset E, Pham T, Marotte H, Servettaz A, Domont F, Chazerain P, Devaux M, Claudepierre P, Langlois V, Mekinian A, Maria ATJ, Banneville B, Fautrel B, Pouchot J, Thomas T, Flipo RM, Richez C; FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors., FAIR/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol 2021;3:e419-26. [PMID: 33786454 DOI: 10.1016/S2665-9913(21)00059-X] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 29.0] [Reference Citation Analysis]
36 Palandri F, Di Pietro C, Ricci F, Tazzari PL, Randi V, Bartoletti D, Cavo M, Vianelli N, Auteri G. Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies. Res Pract Thromb Haemost 2021;5:e12606. [PMID: 34938937 DOI: 10.1002/rth2.12606] [Reference Citation Analysis]
37 Hirzel C, Grandgirard D, Surial B, Wider MF, Leppert D, Kuhle J, Walti LN, Schefold JC, Spinetti T, Suter-riniker F, Dijkman R, Leib SL. Neuro-axonal injury in COVID-19: the role of systemic inflammation and SARS-CoV-2 specific immune response. Ther Adv Neurol Disord 2022;15:175628642210805. [DOI: 10.1177/17562864221080528] [Reference Citation Analysis]
38 Basheer M, Saad E, Laskar O, Schuster O, Rechnitzer H, Zisman-Rozen S, Azoulay D, Assy N. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery. Int J Mol Sci 2021;22:8902. [PMID: 34445605 DOI: 10.3390/ijms22168902] [Reference Citation Analysis]
39 Gerber V, Velay A, Boehn L, Solis M, Kaeuffer C, Rougier E, Ursenbach A, Hansmann Y, Lefebvre N, Danion F, Ruch Y. Protracted SARS-CoV-2 pneumonia with rituximab treatment: About two cases. J Med Virol 2021;93:4141-4. [PMID: 33666242 DOI: 10.1002/jmv.26921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
40 Clark E, Guilpain P, Filip IL, Pansu N, Le Bihan C, Cartron G, Tchernonog E, Roubille C, Morquin D, Makinson A, Tuaillon E, Le Moing V. Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. Br J Haematol 2020;190:e154-6. [PMID: 32593180 DOI: 10.1111/bjh.16981] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
41 Martín Navarro JA, Cintra Cabrera M, Lucca Proccacini F, Muñoz Rodríguez J, Roldán Cortés D, Lucena Valverde R, Ortega Díaz M, Puerta Carretero M, Gil Herrera J, Jaldo Rodríguez MT, Albalate Ramón M, Corchete Prats E, Medina Zahonero L, de Sequera Ortiz P, Alcázar Arroyo R. More difficult still: Treating severe rapidly progressive glomerulonephritis in the context of COVID-19 pneumonia. Nefrologia (Engl Ed) 2021:S0211-6995(21)00012-6. [PMID: 33781578 DOI: 10.1016/j.nefro.2020.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Zimmerli A, Monti M, Fenwick C, Eckerle I, Beigelman-Aubry C, Pellaton C, Jaton K, Dumas D, Stamm GM, Infanti L, Andreu-Ullrich H, Germann D, Mean M, Vollenweider P, Stadelmann R, Prella M, Comte D, Guery B, Gachoud D, Rufer N. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery. Front Immunol 2021;12:613502. [PMID: 33968017 DOI: 10.3389/fimmu.2021.613502] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Gaitzsch E, Passerini V, Khatamzas E, Strobl CD, Muenchhoff M, Scherer C, Osterman A, Heide M, Reischer A, Subklewe M, Leutbecher A, Tast B, Ruhle A, Weiglein T, Stecher SS, Stemmler HJ, Dreyling M, Girl P, Georgi E, Wölfel R, Mateyka L, D'Ippolito E, Schober K, Busch DH, Kager J, Spinner CD, Treiber M, Rasch S, Lahmer T, Iakoubov R, Schneider J, Protzer U, Winter C, Ruland J, Quante M, Keppler OT, von Bergwelt-Baildon M, Hellmuth J, Weigert O. COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma. Hemasphere 2021;5:e603. [PMID: 34235400 DOI: 10.1097/HS9.0000000000000603] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Chihara D, Kreitman RJ. Treatment of hairy cell leukemia. Expert Rev Hematol 2020;13:1107-17. [PMID: 32893700 DOI: 10.1080/17474086.2020.1819231] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Kremer AE, Kremer AN, Willam C, Völkl S, Verhagen J, Achenbach S, van der Meijden ED, Lang V, Aigner M, Maier C, Tenbusch M, Korn K, Lutzny-Geier G, Spoerl S, Strauß R, Vetter M, Überla K, Neurath MF, Mackensen A, Schiffer M, Hackstein H. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity. Eur J Immunol 2021. [PMID: 34350584 DOI: 10.1002/eji.202149277] [Reference Citation Analysis]
46 Ordaya EE, Abu Saleh OM, Stubbs JR, Joyner MJ. Vax-Plasma in Patients With Refractory COVID-19. Mayo Clin Proc 2022;97:186-9. [PMID: 34996552 DOI: 10.1016/j.mayocp.2021.11.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Massalska MA, Gober HJ. How Children Are Protected From COVID-19? A Historical, Clinical, and Pathophysiological Approach to Address COVID-19 Susceptibility. Front Immunol 2021;12:646894. [PMID: 34177895 DOI: 10.3389/fimmu.2021.646894] [Reference Citation Analysis]
48 Grange L, Guilpain P, Truchetet ME, Cracowski JL; French Society of Pharmacology and Therapeutics. Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review. Therapie 2020;75:335-42. [PMID: 32665090 DOI: 10.1016/j.therap.2020.06.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
49 Bektaş M, Özdemir G. Protracted or recurrent COVID-19 associated cytokine storm in a patient with chronic lymphocytic leukemia receiving rituximab-based chemotherapy. Clinical Immunology 2022. [DOI: 10.1016/j.clim.2022.108936] [Reference Citation Analysis]
50 Giesen N, Sprute R, Rüthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, Sandherr M, von Bergwelt-Baildon M, Wolf HH, Hirsch HH, Wörmann B, Cornely OA, Köhler P, Schalk E, von Lilienfeld-Toal M. Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Eur J Cancer 2020;140:86-104. [PMID: 33068941 DOI: 10.1016/j.ejca.2020.09.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
51 Rabascall CX, Lou BX, Navetta-Modrov B, Hahn SS. Effective use of monoclonal antibodies for treatment of persistent COVID-19 infection in a patient on rituximab. BMJ Case Rep 2021;14:e243469. [PMID: 34344651 DOI: 10.1136/bcr-2021-243469] [Reference Citation Analysis]
52 Duléry R, Lamure S, Delord M, Di Blasi R, Chauchet A, Hueso T, Rossi C, Drenou B, Deau Fischer B, Soussain C, Feugier P, Noël N, Choquet S, Bologna S, Joly B, Philippe L, Kohn M, Malak S, Fouquet G, Daguindau E, Taoufik Y, Lacombe K, Cartron G, Thiéblemont C, Besson C. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol 2021;96:934-44. [PMID: 33909916 DOI: 10.1002/ajh.26209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
53 Yasuda H, Mori Y, Chiba A, Bai J, Murayama G, Matsushita Y, Miyake S, Komatsu N. Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections. Clin Lymphoma Myeloma Leuk 2021:S2152-2650(21)00273-1. [PMID: 34393077 DOI: 10.1016/j.clml.2021.07.004] [Reference Citation Analysis]
54 Bisceglia I, Canale ML, Gallucci G, Turazza FM, Lestuzzi C, Parrini I, Russo G, Maurea N, Quagliariello V, Oliva S, Di Fusco SA, Lucà F, Tarantini L, Trambaiolo P, Moreo A, Geraci G, Gabrielli D, Gulizia MM, Oliva F, Colivicchi F. Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story. Front Cardiovasc Med 2022;9:821193. [DOI: 10.3389/fcvm.2022.821193] [Reference Citation Analysis]
55 Schulze-Koops H, Skapenko A, Krause A, Krueger K, Lorenz HM, Sewerin P, Specker C, Wagner UG, Voormann A, Mueller-Ladner U, Voll RE. Correspondence to 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'. Ann Rheum Dis 2020:annrheumdis-2020-218997. [PMID: 33127664 DOI: 10.1136/annrheumdis-2020-218997] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Williamson J, Black L, Black A, Koduri G, Kelly C. There are similarities between rheumatic disease with lung involvement and COVID-19 pneumonia. Ir J Med Sci 2021. [PMID: 33564974 DOI: 10.1007/s11845-021-02545-y] [Reference Citation Analysis]
57 Marcacci G, Fiorentino G, Volzone F, Falcone U, Parrella R, Donnarumma D, D'Ovidio S, Annunziata A, Micallo G, Portella G, De Chiara A, De Filippi R, Crisci S, Pinto A. Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab. Infect Agent Cancer 2021;16:38. [PMID: 34078415 DOI: 10.1186/s13027-021-00376-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
58 Mathian A, Amoura Z. Response to: 'Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian et al' by Notz et al. Ann Rheum Dis 2020:annrheumdis-2020-218795. [PMID: 33239273 DOI: 10.1136/annrheumdis-2020-218795] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
59 Arnold J, Winthrop K, Emery P. COVID-19 vaccination and antirheumatic therapy. Rheumatology (Oxford) 2021;60:3496-502. [PMID: 33710296 DOI: 10.1093/rheumatology/keab223] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
60 Jones JM, Faruqi AJ, Sullivan JK, Calabrese C, Calabrese LH. COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review. Pathog Immun 2021;6:76-103. [PMID: 34056149 DOI: 10.20411/pai.v6i1.435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
61 Bonelli MM, Mrak D, Perkmann T, Haslacher H, Aletaha D. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. Ann Rheum Dis 2021;80:1355-6. [PMID: 33958323 DOI: 10.1136/annrheumdis-2021-220408] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
62 Delgado-Fernández M, García-Gemar GM, Fuentes-López A, Muñoz-Pérez MI, Oyonarte-Gómez S, Ruíz-García I, Martín-Carmona J, Sanz-Cánovas J, Castaño-Carracedo MÁ, Reguera-Iglesias JM, Ruíz-Mesa JD. Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature. Enferm Infecc Microbiol Clin (Engl Ed) 2021:S0213-005X(21)00035-5. [PMID: 33741148 DOI: 10.1016/j.eimc.2021.01.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
63 Horiuchi H, Sasaki H, Miyazaki K, Miyata N, Yoshimura Y, Tachikawa N. Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab. J Infect Chemother 2021:S1341-321X(21)00329-9. [PMID: 34887178 DOI: 10.1016/j.jiac.2021.11.018] [Reference Citation Analysis]
64 Bonuomo V, Ferrarini I, Dell'Eva M, Sbisà E, Krampera M, Visco C. COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review. World J Virol 2021; 10(6): 312-325 [PMID: 34909405 DOI: 10.5501/wjv.v10.i6.312] [Reference Citation Analysis]
65 Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021;184:861-80. [PMID: 33497610 DOI: 10.1016/j.cell.2021.01.007] [Cited by in Crossref: 172] [Cited by in F6Publishing: 178] [Article Influence: 172.0] [Reference Citation Analysis]
66 Aapro M, Lyman GH, Bokemeyer C, Rapoport BL, Mathieson N, Koptelova N, Cornes P, Anderson R, Gascón P, Kuderer NM. Supportive care in patients with cancer during the COVID-19 pandemic. ESMO Open 2021;6:100038. [PMID: 33421735 DOI: 10.1016/j.esmoop.2020.100038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
67 Webb BJ. Defining COVID-19-associated hyperinflammatory syndrome in specific populations. Lancet Rheumatol 2021;3:e609-11. [PMID: 34095856 DOI: 10.1016/S2665-9913(21)00157-0] [Reference Citation Analysis]
68 Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Watanabe M, Saeki M, Hirakawa Y, Sakai R, Matsumoto S, Mizutani Y, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito M, Nishimura M, Imamura Y, Kiyota N, Matsuoka H, Mori Y, Minami H. Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody. Int J Hematol 2022;115:7-10. [PMID: 34981433 DOI: 10.1007/s12185-021-03247-y] [Reference Citation Analysis]
69 Levavi H, Lancman G, Gabrilove J. Impact of rituximab on COVID-19 outcomes. Ann Hematol 2021;100:2805-12. [PMID: 34549309 DOI: 10.1007/s00277-021-04662-1] [Reference Citation Analysis]
70 Fujii H, Tsuji T, Sugitani M, Matsumoto Y, Yuba T, Tanaka S, Suga Y, Matsuyama A, Goda S, Omura A, Shiotsu S, Takumi C, Ono S, Hiraoka N. Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report. Curr Probl Cancer 2021;:100739. [PMID: 33810911 DOI: 10.1016/j.currproblcancer.2021.100739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]